Next Article in Journal
Next Article in Special Issue
Previous Article in Journal
Previous Article in Special Issue
Cancers 2010, 2(2), 624-641; doi:10.3390/cancers2020624
Review

Midkine: A Novel Prognostic Biomarker for Cancer

*  and
Received: 5 March 2010; in revised form: 3 March 2010 / Accepted: 19 April 2010 / Published: 20 April 2010
(This article belongs to the Special Issue Biomarkers: Oncology Studies)
View Full-Text   |   Download PDF [410 KB, updated 20 April 2010; original version uploaded 20 April 2010]
Abstract: Since diagnosis at an early stage still remains a key issue for modern oncology and is crucial for successful cancer therapy, development of sensitive, specific, and non-invasive tumor markers, especially, in serum, is urgently needed. Midkine (MK), a plasma secreted protein, was initially identified in embryonal carcinoma cells at early stages of retinoic acid-induced differentiation. Multiple studies have reported that MK plays important roles in tumor progression, and is highly expressed in various malignant tumors. Because increased serum MK concentrations also have been reported in patients with various tumors, serum MK may have the potential to become a very useful tumor marker. Here, we review and discuss the possibility and usefulness of MK as a novel tumor marker.
Keywords: Midkine; tumor marker; cancer screening; prognostic prediction Midkine; tumor marker; cancer screening; prognostic prediction
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Jono, H.; Ando, Y. Midkine: A Novel Prognostic Biomarker for Cancer. Cancers 2010, 2, 624-641.

AMA Style

Jono H, Ando Y. Midkine: A Novel Prognostic Biomarker for Cancer. Cancers. 2010; 2(2):624-641.

Chicago/Turabian Style

Jono, Hirofumi; Ando, Yukio. 2010. "Midkine: A Novel Prognostic Biomarker for Cancer." Cancers 2, no. 2: 624-641.



Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert